Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 10/20 | 0.44 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4276964 | 0.74 | CHRM3 (0.58) | CHRM3CYP2B6ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL1072704 | 0.73 | CYP2B6 (0.59) | CHRM3CYP2B6GAAMEN1KMT2A | |
| SCHEMBL11019030 | 0.71 | CHRM3 (0.43) | CHRM3CYP2B6ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL27300905 | 0.70 | SMN1; SMN2 (0.39) | ALDH1A1SMN1; SMN2GAAMEN1KMT2A | |
| SCHEMBL2126693 | 0.69 | CHRM3 (0.61) | CHRM3ALDH1A1SMN1; SMN2 | |
| SCHEMBL2574350 | 0.69 | SMN1; SMN2 (0.38) | ALDH1A1SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL2344856 | 0.69 | SMN1; SMN2 (0.38) | ALDH1A1SMN1; SMN2GAAMEN1KMT2A | |
| SCHEMBL3308712 | 0.68 | CHRM3 (0.45) | CHRM3ALDH1A1MEN1KMT2ASIGMAR1 | |
| SCHEMBL28118249 | 0.67 | CNR1 (0.38) | ALDH1A1SMN1; SMN2GAAMEN1KMT2A | |
| SCHEMBL27746719 | 0.67 | SMN1; SMN2 (0.37) | SMN1; SMN2MEN1KMT2ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113510-A1 | QUINUCLIDINOL DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113510-A1 | QUINUCLIDINOL DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885CYP2B6 401/4885ALDH1A1 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.